Thomas Pitts, MD
Neurology · New York, NYNPI 1750624656
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,854 of the $211,241 with a category attached, or 79.5%. AstraZeneca accounts for 94.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $102,612 and has fallen 97.8% since, to $2,303 in 2023. Among neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $407.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$200K
- Catalyst Pharmaceuticals, Inc.$7K
- Amgen$1K
- Biohaven Pharmaceuticals, Inc.$387
- AbbVie$342
- Teva Pharmaceuticals USA, Inc.$305
- plus $2K from 21 others
What the payments were for
- Consulting fees$6,3583%
- Speaking & faculty fees$167,85479%
- Travel & lodging$28,59014%
- Food & beverage$8,3404%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 356 | $200,228 |
| Catalyst Pharmaceuticals, Inc. | 14 | $7,315 |
| Amgen(2 entities) | 30 | $1,014 |
| Biohaven Pharmaceuticals, Inc. | 13 | $387 |
| AbbVie(2 entities) | 15 | $342 |
| Teva Pharmaceuticals USA, Inc. | 11 | $305 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $274 |
| Novartis | 13 | $240 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $227 |
| Medtronic | 5 | $174 |
| Nevro Corp. | 2 | $131 |
| MDD US Operations, LLC | 4 | $83 |
| Redhill Biopharma Inc. | 4 | $62 |
| Lundbeck LLC | 3 | $58 |
| Biogen | 3 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 3 | $43 |
| Almatica Pharma LLC | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Johnson & Johnson | 2 | $36 |
| Akcea Therapeutics, Inc. | 1 | $28 |
| Boston Scientific | 1 | $22 |
| Bioventus LLC | 1 | $19 |
| Pfizer | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Forte Bio-pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$158,128
- ULTOMIRIS$21,670
- FIRDAPSE$7,150
- NURTEC ODT$245
- UPLIZNA$200
- Senza Spinal Cord Stimulation System$106
How this compares
$211,241 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.